Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis
出版年份 2019 全文链接
标题
Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis
作者
关键词
-
出版物
Science Translational Medicine
Volume 11, Issue 520, Pages eaav9701
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2019-11-28
DOI
10.1126/scitranslmed.aav9701
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PS-106-An international, randomized, placebo-controlled phase 2 trial demonstrates novel effects of DGAT2 antisense inhibition in reducing steatosis without causing hypertriglyceridemia in T2DM patients
- (2019) Rohit Loomba et al. JOURNAL OF HEPATOLOGY
- DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates
- (2018) David G. McLaren et al. Cell Metabolism
- An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans
- (2018) Adil Mardinoglu et al. Cell Metabolism
- Mechanistic Characterization of Long Residence Time Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)
- (2018) Brandon Pabst et al. BIOCHEMISTRY
- Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib
- (2018) Saumya Jayakumar et al. JOURNAL OF HEPATOLOGY
- Exome chip meta-analysis identifies novel loci and East Asian–specific coding variants that contribute to lipid levels and coronary artery disease
- (2017) Xiangfeng Lu et al. NATURE GENETICS
- Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
- (2017) Anna M. Diehl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- (2017) A. Michael Lincoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Roles of Acyl-CoA:Diacylglycerol Acyltransferases 1 and 2 in Triacylglycerol Synthesis and Secretion in Primary Hepatocytes
- (2015) C. Li et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop
- (2015) Arun J. Sanyal et al. HEPATOLOGY
- The Diacylglycerol Acyltransferase 1 Inhibitor, Pradigastat, Was Well Tolerated in a 52-Week Clinical Trial in FCS Patients
- (2015) Erik S.G. Stroes et al. Journal of Clinical Lipidology
- Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)
- (2015) Kentaro Futatsugi et al. JOURNAL OF MEDICINAL CHEMISTRY
- NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels
- (2014) K. E. Corey et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- World Gastroenterology Organisation Global Guidelines
- (2014) Douglas R. LaBrecque et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Intestine-Targeted DGAT1 Inhibition Improves Obesity and Insulin Resistance without Skin Aberrations in Mice
- (2014) Naoto Tsuda et al. PLoS One
- Non-alcoholic fatty liver disease
- (2014) N. Sattar et al. BMJ-British Medical Journal
- Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia
- (2013) Victor A. Zammit BIOCHEMICAL JOURNAL
- Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial
- (2013) H. Denison et al. DIABETES OBESITY & METABOLISM
- The DGAT1 inhibitor Pradigastat Decreases Chylomicron Secretion and Prevents Postprandial Triglyceride Elevation in Humans
- (2013) Charles Daniel Meyers et al. Journal of Clinical Lipidology
- A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma
- (2013) Masato Fujii et al. Medical Molecular Morphology
- Smooth Muscle α Actin (Acta2) and Myofibroblast Function during Hepatic Wound Healing
- (2013) Don C. Rockey et al. PLoS One
- Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD
- (2012) Z. Permutt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging
- (2012) Arian Mashhood et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Targeting Acyl-CoA:Diacylglycerol Acyltransferase 1 (DGAT1) with Small Molecule Inhibitors for the Treatment of Metabolic Diseases
- (2011) Jingsong Cao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites
- (2010) Brent A. Neuschwander-Tetri HEPATOLOGY
- Histopathology of nonalcoholic fatty liver disease
- (2010) Elizabeth M Brunt WORLD JOURNAL OF GASTROENTEROLOGY
- Obesity-Associated Liver Disease
- (2008) Giulio Marchesini et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Thematic Review Series: Glycerolipids.DGAT enzymes and triacylglycerol biosynthesis
- (2008) Chi-Liang Eric Yen et al. JOURNAL OF LIPID RESEARCH
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
- (2008) Stefano Romeo et al. NATURE GENETICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started